Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European ... (as measured by 24-hour urine protein to creatinine ratio [UPCR]) at 6 months ...
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has decided it cannot approve ... blocking the effects of the protein sclerostin and as a consequence building new bone formation.
(RTTNews) - AstraZeneca (AZN.L, AZN) announced Imfinzi was recommended for approval in the European Union by CHMP as first and only immunotherapy for limited-stage small cell lung cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback